ARTICLE | Company News
BioLineRx, Genoscience, RFS deal
February 13, 2012 8:00 AM UTC
BioLineRx received exclusive, worldwide rights from Genoscience and RFS Pharma to BL-8030, an HCV NS3 protease inhibitor in preclinical development. BioLineRx expects to begin clinical trials in 18-24 months. ...